A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers

M. Cortellaro, C. Boschetti, V. Antoniazzi, E. E. Polli, G. de Gaetano, A. De Blasi, M. Gerna, L. Pezzi, S. Garattini

Research output: Contribution to journalArticlepeer-review

Abstract

In a double-blind study on healthy subjects who underwent three 3-week periods of treatment with metoprolol (M) + sulfinpyrazone (S), M + placebo, and S + placebo, pharmacokinetics and plasma levels of M were not affected by concurrent administration of S. Analysis of variance change-over demonstrated a significant difference between treatments only for serum uric acid levels. Analysis of post-treatment and baseline data within each treatment showed: decreased platelet count by M, lowered serum 6-keto PGF by all three treatments, decreased serum TXB2 generation and arachidonic acid-induced platelet aggregation by S + M. No negative interaction between S + M was found.

Original languageEnglish
Pages (from-to)65-74
Number of pages10
JournalThrombosis Research
Volume34
Issue number1
DOIs
Publication statusPublished - Apr 1 1984

Keywords

  • Metoprolol
  • platelet function
  • sulfinpyrazone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Fingerprint

Dive into the research topics of 'A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers'. Together they form a unique fingerprint.

Cite this